| John Rasko, AO, MBBS, PhD, FRCPA, FRACP, FAHMS Vice – Chair (June 2019-2020) Royal Prince Alfred Hospital Sydney, Australia |
| [1] Berger I, Ahmad A, Bansal A, Kapoor T, Sipp D, Rasko JEJ. Global Distribution of Businesses Marketing Stem Cell-Based Interventions. Cell Stem Cell 2016;19(2):158-162. https://doi.org/10.1016/j.stem.2016.07.015 [2] Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ. Marketing of Unproven Stem Cell-Based Interventions: A Call to Action. Science Translational Medicine 2017;9(397). https://doi.org/10.1126/scitranslmed.aag0426 [3] Sipp D, McCabe C, Rasko JEJ. Show drugs work before selling them. Nature 2017;543:174-175. doi:10.1038/543174a [4] Power C and Rasko JEJ. Promises and challenges of stem cell research for regenerative medicine. Annals of Internal Medicine 2011;155(10):706-U91. https://doi.org/10.7326/0003-4819-155-10-201111150-00010 [5] Rasko JEJ, O’Sullivan G, Ankeny R (2006). The ethics of inheritable genetic modification: a dividing line? Cambridge University Press. |